Acutaas Chemicals Limited, formerly Ami Organics Limited, is a manufacturer of pharma intermediates and specialty chemicals. It is focused on the development and manufacturing of advanced pharmaceutical intermediates (Pharma Intermediates), New Chemical Entities (NCE) and other specialty chemicals for pharmaceuticals, agrochemicals, dyes, polymers, personal care, animal food, and other industries. It manufactures pharma intermediates for certain active pharmaceutical ingredients (APIs), including dolutegravir, trazodone, entacapone, nintedanib, and rivaroxaban. The pharma intermediates cater to several therapeutic areas, including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant. It has developed and commercialized over 520 plus products, including specialty chemicals, Pharma Intermediates for APIs across 23 key therapeutic areas since inception and NCE across select high-growth high margin chronic therapeutic areas.
Acutaas Chemicals (formerly Ami Organics) manufactures advanced pharmaceutical intermediates and specialty chemicals, supplying building blocks (N-1 to N-8 stage) to global API makers across 23 therapeutic areas including anti-retroviral, anti-cancer, and anti-Parkinson drugs. [IndianAPI]
The company operates across three revenue verticals: (1) Pharma Intermediates (~84% of revenue), supplying intermediates for APIs like dolutegravir, trazodone, entacapone, nintedanib, and rivaroxaban; (2) Specialty Chemicals (~16%), including KSMs for agrochemicals, fine chemicals, parabens, and UV absorbers; and (3) an emerging Electrolyte Additives business for lithium-ion batteries, not yet at meaningful revenue scale. [IndianAPI] [ValuePickr]
Geographically, exports contributed approximately 37% and domestic sales 63% as of the most recent disclosed split. The company has commercialized 520+ products since inception and added ~60 new customers and 70 new products in FY23 alone. [ValuePickr]
Revenue reached ₹1,007 Cr in FY25, up from ₹717 Cr in FY24 — a YoY growth of 40.4%. TTM revenue stands at ₹1,215 Cr with a 5-year revenue CAGR of 28.9%. [Screener] [Computed]
The differentiated portion is the R&D-driven intermediate portfolio where management claims 50-90% global market share in select molecules per the DRHP — a figure that is self-reported and not independently verified — achieved by developing intermediates early in a drug's clinical trial phase and embedding itself in customers' Drug Master Files (DMFs). The commodity-exposed portion is the specialty chemicals segment, where Chinese competition creates pricing pressure. [ValuePickr]
The primary moat is first-mover advantage in pharma intermediates for chronic-therapy APIs. The company develops intermediates during the clinical trial phase of new drugs — years before competitors — and locks in positions in customers' DMFs. Switching costs are high because changing an intermediate supplier requires re-validation with regulators, a process that takes 12-18 months. Management states 50-90% global market share in select key molecules (DRHP-sourced, self-reported, not independently verified). 91% of the pharma intermediate portfolio caters to chronic therapies. [ValuePickr]
The multi-year exclusive supply agreement with Fermion (a Finnish innovator pharma company) for on-patent API intermediates validates this lock-in strategy. The contract scope expanded from 1 to 3 products. However, the exact revenue quantum remains undisclosed by management. [ValuePickr]
The company has adopted continuous flow chemistry technology for high-volume products (e.g., methyl salicylate), achieving 3x capacity expansion with 5-7% cost savings — a process technology edge that smaller Indian competitors lack. [ValuePickr]
Closest competitors in the Indian pharma intermediate space include Aarti Industries (larger, more diversified), PI Industries (CSM-focused, agrochem-heavy), and Neogen Chemicals (lithium chemistry overlap). Acutaas differs by its narrow focus on chronic-therapy pharma intermediates and early-stage molecule development, though this concentration also creates customer-dependency risk. [ValuePickr]
The electrolyte additives business (for Li-ion batteries) is a potential second growth leg — Acutaas claims to be the first company outside China to develop these additives. Samples are approved by 6 customers, but commercial revenue is yet to materialize in a meaningful way, and execution risk remains. [ValuePickr]
Promoter holding stands at 32.66% as of Dec 2025, down from 39.41% in Mar 2023 — a decline of 6.75 percentage points over roughly 3 years. [Screener] This is a key governance concern. However, the Chovatia family, classified as public shareholders, holds an estimated ~17% stake and appears closely allied with the promoters per public domain disclosures, bringing effective promoter-aligned holding closer to ~50%. [ValuePickr]
The company is led by Mr. Nareshkumar Ramjibhai Patel (age 51), Executive Chairman & MD, who founded the company in 2004. Other key personnel include Mr. Chetanbhai Vaghasia (Whole Time Director), Mr. Virendra Nath Mishra (Whole Time Director), Mr. Bhavin Shah (CFO, age 47), and Dr. Ajit Choubey (President of Technical & Head R&D, age 69). [IndianAPI]
Capital allocation has been growth-oriented: the company raised ₹300 Cr via IPO (Sep 2021), repaid ₹140 Cr debt, pursued the Gujarat Organics acquisition, the Baba Fine Chemicals acquisition (55% stake, semiconductor chemicals), and most recently acquired 75% of Indichem Inc (South Korea) for battery chemical manufacturing, with plant commissioning expected by end-2026. [ValuePickr] [IndianAPI]
Dividend payout has been modest — ₹1.5/share (FY25) and ₹3/share (FY24, FY23, FY22) on a face value of ₹5. The dividend payout ratio was 8% in FY25 and 26% in FY24, indicating management prefers reinvestment over cash returns. [Screener] [IndianAPI]
Governance flags: Two preferential equity issues (Apr 2023, Aug 2023) within ~19 months of IPO raised dilution concerns on ValuePickr forums. Promoter remuneration was 1.5% of sales in FY23. The working capital cycle has been persistently stretched at 123 days in FY25, and free cash flow has been negative for at least 5 consecutive years — the company has relied on equity and debt raises to fund growth. [Screener] [ValuePickr]
Acutaas operates in the Indian specialty chemicals / pharma intermediates sector, classified as Chemical Manufacturing. [IndianAPI] The Indian specialty chemicals market was estimated at ~US$80 billion (2024) with expected growth rates of 11-12% CAGR, driven by China+1 sourcing diversification by global pharma companies. [ValuePickr]
The business has uncertain cyclicality: management positions the pharma intermediate segment as structurally resilient due to DMF lock-ins, but the FY24 margin squeeze to 18% OPM (from 20% in FY23) under Chinese pricing pressure suggests meaningful cyclical exposure remains. OPM has recovered to 31% on a TTM basis, but whether this reflects a structural margin step-up or a cyclical peak is not yet determinable from available data. [Screener]
Two regulatory tailwinds are relevant: (1) India's push for PLI schemes in battery chemicals and semiconductors — directly relevant to the electrolyte additives and Baba Fine Chemicals businesses; (2) stricter environmental regulations in China that have raised costs for Chinese competitors. The headwind is that if Chinese export pricing normalizes, margin compression could return in the specialty chemicals segment. [ValuePickr]
Naresh Patel, Chairman & Managing Director
Based on the strength of our current order book, we are revising our revenue guidance upwards from 25% to around 30% growth for FY '26. [Concall Q3 FY26]
Revenue from operations hit ₹393.2 Cr in Q3 FY26, up 43% YoY, with 9-month revenue at ₹906.6 Cr (+29.8% YoY). The Pharma Intermediates segment delivered ₹351.1 Cr (+47% YoY), driven primarily by CDMO business. Management upgraded full-year revenue growth guidance from 25% to ~30%, implying FY26 revenue of ~₹1,309 Cr. [Concall Q3 FY26]
The CDMO business remains the dominant growth engine. Abhishek Patel confirmed five commercialized CDMO products as of Q3, with four additional products validated in FY26. Management reiterated the target of ₹1,000 Cr CDMO revenue by FY28 — but notably refused to disclose 9-month CDMO contribution or product-level split, citing confidentiality. Naresh Patel clarified this ₹1,000 Cr target is a bundle of several CDMO contracts, not solely the flagship anticancer molecule. [Concall Q3 FY26]
Non-CDMO pharma intermediates grew at high single digits, which management characterized as deliberate — they are churning out low-margin legacy products and focusing on quality growth. Apixaban and rivaroxaban were named as performing well on the generic side. [Concall Q3 FY26]
EBITDA margin guidance was upgraded from 28-30% (Q2 FY26 call) to 32-35% for full-year FY26. Q3 FY26 EBITDA margin printed at a record 38.3%, up 1,335 bps YoY. Gross margin expanded to 57%, driven by product mix shift towards higher-value CDMO. Segmental EBITDA: Pharma at ~41%, Specialty Chemicals at ~12%. [Concall Q3 FY26]
The margin trajectory has been dramatic: from ~20% OPM in FY24 quarters to 38% in Q3 FY26. Management attributed this to a combination of (a) CDMO mix shift, (b) process improvements and flow chemistry conversions, (c) solar power cost savings from their 15.8 MW plant, and (d) systematic pruning of low-margin products. CFO Bhavin Shah confirmed energy cost savings and internal process optimization drove the reduction in other expenses. [Concall Q3 FY26]
When pressed on FY27 margin sustainability, Abhishek Patel declined to guide, stating they would discuss at a relevant time. The incoming battery chemicals business will carry margins below Pharma Intermediates but above commodity chemicals (the paraben business), which could be dilutive to blended margins once it scales. [Concall Q3 FY26]
Battery chemicals: Jhagadia facility Phase 1 was inaugurated on 19 January 2026, with trial production and validation underway. Commercial supply of VC (vinyl carbonate) and FEC (fluoroethylene carbonate) expected by Q4 FY26 end, with meaningful revenue from Q1 FY27. Total capacity: 2,000 MT each for VC and FEC (4,000 MT combined). Management confirmed orders already in hand with good visibility for FY27. Phase 2 capex of ₹40 Cr for two additional battery chemical products is underway, expected completion by Q1 FY27. [Concall Q3 FY26]
Semiconductor chemicals: (a) Baba Fine Chem (BFC) — the Japan-facing subsidiary has turned around, with Abhishek Patel noting Q2 was the bottom and traction is improving from Q3 onward, driven by marketing non-Heraeus products to new geographies. No revenue guidance given for BFC. (b) Indichem JV (South Korea) — ₹130 Cr invested so far out of ~₹200 Cr total. Capex expected complete by calendar year 2026, commercial revenue from H2 FY27. Asset turnover guided at ~1x with higher EBITDA margins than pharma. [Concall Q3 FY26]
Total FY26 cash outflow: ₹220 Cr capex (electrolyte + pilot plant + maintenance + solar) plus ₹130 Cr Indichem investment = ~₹350 Cr. Capex was revised down from ₹250 Cr guided earlier, as Phase 2 electrolyte and pilot plant capex spilled over. Net cash was ₹129.5 Cr as of Dec 2025 (down from ₹240.6 Cr in Sep 2025), reflecting the heavy investment phase. [Concall Q3 FY26]
Working capital days stood at 111 days in Q3 FY26 — debtors at 100 days, inventory at 55 days, payables at 44 days. This deteriorated from 100 days in Q2 FY26, primarily on higher debtor days. Management maintains 110 days is the standard comfortable level for their business, with aspiration to bring it to 100. [Concall Q3 FY26]
The company remains nearly debt-free with D/E of 0.01 [Screener]. However, the heavy capex phase (₹350 Cr in FY26) has drawn down cash from ₹249 Cr at FY25-end to ₹129.5 Cr at Q3 FY26-end. Management asserted they have sufficient cash flow generation to fund remaining outlays without external debt. [Concall Q3 FY26]
| Metric | Guided | Actual | Status |
|---|---|---|---|
| Revenue Growth FY26 | 25% → revised to 30% | 29.8% (9M YoY) | On track |
| EBITDA Margin FY26 | 28-30% → revised to 32-35% | 32.7% (9M avg) | On track |
| Capex FY26 | ₹250 Cr → revised to ₹220 Cr | ₹143 Cr (9M) | Spillover to FY27 |
| Battery Chemicals Launch | H2 FY26 production start | Plant inaugurated Jan 2026, trial batches ongoing | Delayed by ~1 quarter |
| Pilot Plant Completion | Q3 FY26 | Expected Q1 FY27 (equipment delay) | Delayed |
| Indichem Capex | ~₹200 Cr total | ₹130 Cr invested, rest pending | On track |
| CDMO Revenue FY28 | ₹1,000 Cr | 5 products commercialized, 4 more validated | Building pipeline |
| Working Capital Days | 95-105 days (Q2 guidance) | 111 days (Q3 FY26) | Missed |
Revenue and margin guidance have been <strong>upgraded twice</strong> during FY26, reflecting genuine business momentum. However, capex timelines have slipped — electrolyte Phase 2 and pilot plant both pushed to FY27. Working capital has also deteriorated despite the guidance of sub-105 days. Management credibility is high on revenue delivery (25%+ CAGR maintained for 15+ years per their claim) but capex execution timelines carry a pattern of 1-quarter delays. [Concall Q3 FY26]
1. Negative FCF for 5+ years is masked by accounting profits. Acutaas reported ₹160 Cr PAT in FY25, but FCF was -₹76 Cr. FY25 CFO/PAT of 0.74x (₹118 Cr / ₹160 Cr) is improving from prior years but still sub-par cash conversion — and the multi-year weighted average since FY20 is far worse given negative CFO in FY22. The company has funded growth through IPO proceeds (₹300 Cr), preferential issues, and drawdowns of cash reserves — not through self-sustaining cash flows. At some point, this gap must close or further dilution becomes necessary. The market is pricing 60x on PAT, not on FCF — which is currently zero. [Screener] [Computed]
2. Three new verticals launching simultaneously creates compounding execution risk. Battery chemicals (Jhagadia), semiconductor chemicals (Indichem Korea + BFC Japan), and CDMO scale-up are all entering commercial phase between Q4 FY26 and H2 FY27. Each requires different supply chains, customer relationships, and technical capabilities. Management bandwidth is finite — the core team (CMD Naresh Patel, Abhishek Patel, CFO Bhavin Shah) is stretching across pharma, battery, and semiconductor operations across India, South Korea, and Japan. No COO or dedicated vertical heads have been announced. [Concall Q3 FY26] [IndianAPI]
3. Working capital dynamics may worsen as CDMO scales. CDMO contracts with large innovator pharma companies typically carry longer payment terms (90-120 days) than generic pharma intermediates. As CDMO rises from an undisclosed share to a targeted ₹1,000 Cr by FY28, debtor days could structurally increase — precisely the opposite of what management guided (95-105 days target). Q3 FY26 already showed debtor days jumping from 87 to 100 days in one quarter. [Concall Q3 FY26] [Screener]
At 60.2x P/E and 41.1x EV/EBITDA, the stock prices in ~30% earnings CAGR for 3+ years with no execution misses. Any margin disappointment (e.g., battery chemicals drag on blended OPM) or working capital deterioration could trigger a 25-35% de-rating — bringing P/E to 40-45x, which still implies a premium valuation for a specialty chemicals company. [Screener] [Computed]
Promoter-aligned stake sales classified as public. The Chovatia family (~17% stake) sold 5.21% in Sep 2022 despite being classified as 'close to promoters' on ValuePickr. Further sales by this group would effectively function as promoter dilution without appearing in the formal promoter holding data. Monitor bulk/block deal disclosures quarterly. [ValuePickr]
Capex timeline slippage is a pattern, not an exception. Battery chemicals launch delayed ~1 quarter. Pilot plant delayed from Q3 FY26 to Q1 FY27. Ankleshwar brownfield capex timeline was pushed during FY24. Management credibility on revenue delivery is high (25%+ CAGR for 15+ years), but capex execution consistently runs 1-2 quarters behind guidance. Each delay pushes revenue recognition into the next fiscal year, creating short-term earnings misses. [Concall Q3 FY26]
Opacity on CDMO product-level revenue. Despite CDMO being the primary margin and revenue driver, management refuses to disclose (a) 9-month CDMO revenue, (b) product-level splits, and (c) customer concentration within CDMO. This makes it impossible for external analysts to verify the ₹1,000 Cr FY28 target or assess single-contract dependency risk. The Fermion contract scope expansion (1→3 products) is positive but unquantified in revenue terms. [Concall Q3 FY26]
None of these flags individually constitute a dealbreaker, but the combination of promoter dilution + persistent negative FCF + capex delays + revenue opacity suggests investors should apply a higher-than-usual discount rate when valuing future cash flows.
HOLD at ₹2,110 — CDMO-powered compounder priced for perfection across 3 unproven verticals
Acutaas Chemicals has delivered a 5-year revenue CAGR of 28.9% and TTM PAT of ₹285 Cr, driven by a CDMO-led margin expansion from 18% OPM (FY24) to 31% TTM. [Computed] [Screener] The investment case rests on three simultaneous new-vertical launches — CDMO scale-up to ₹1,000 Cr by FY28, battery chemicals at Jhagadia (4,000 MT VC+FEC), and semiconductor chemicals via Indichem Korea — each carrying distinct execution risks. [Concall Q3 FY26] At 60.2x P/E and 41.1x EV/EBITDA, the stock prices in flawless execution across all three verticals over the next 2-3 years. [Screener] The key upside catalyst is CDMO revenue visibility improving beyond the current ₹1,000 Cr FY28 target as new molecules commercialize. The key risk that could break the thesis is margin compression as lower-margin battery chemicals dilute blended OPM, combined with persistent negative FCF (5+ consecutive years) and a stretched working capital cycle of 121 days. [Computed] [Concall Q3 FY26] Analyst consensus is Buy (5 of 6 analysts), but with one Sell rating flagging valuation concerns. [IndianAPI] On a 2-3 year horizon, the risk-reward at current levels is balanced — not compelling enough for fresh accumulation, but existing holders should hold for execution delivery over FY27-28.
| Company | Rev CAGR 3Y | OPM % | ROCE % | P/E | Verdict |
|---|---|---|---|---|---|
| PI Industries | ~20% | 22-24% | 22-25% | ~35x | Better diversified, lower risk |
| Aarti Industries | ~8% | 16-18% | 10-12% | ~45x | Larger but slower growth |
| ACUTAAS | 25.3% | 31% (TTM) | 19.9% | 60.2x | Highest growth, richest valuation |
| Neogen Chemicals | ~22% | 16-18% | 10-12% | ~55x | Li-ion overlap, lower margins |
| Clean Science | ~12% | 40-45% | 30-35% | ~50x | Superior margins, slower growth |
Peer data is directional, based on publicly available trailing data from Screener.in. Acutaas trades at the highest P/E among peers despite having the lowest ROCE and negative FCF. PI Industries offers comparable growth with better capital efficiency and lower valuation risk. [Screener] [ValuePickr]
In one line: Acutaas is a fast-growing specialty chemicals company betting on three new businesses simultaneously — if they all work, the bull case implies ~20% upside to ₹2,520; if any one fails, the current price has limited margin of safety.
Best case: All three new verticals (pharma CDMO, battery chemicals, semiconductor chemicals) hit their targets, margins stay above 28%, and the stock re-rates to ₹2,500+ over 2-3 years — roughly 20% upside from here.
Worst case: CDMO concentration on one molecule leads to a revenue shock, battery/semiconductor plants face delays, margins revert to 18% (like FY24), and the valuation multiple contracts from 60x to 25x — implying a 75% downside to ~₹475. This is the price of paying a premium for growth that has not yet materialized.
Key watchpoint: Watch Q4 FY26 results (expected May 2026) for two things: (1) whether battery chemicals report their first commercial revenue, and (2) whether management gives FY27 margin guidance. Refusal to guide on margins again would signal they expect compression.